Oncoinvent Grants New Chief Medical Officer Zuzana Jirakova Trnkova 20,000 Share Options at NOK 67.35

Oncoinvent granted its new Chief Medical Officer, Dr Zuzana Jirakova Trnkova, 20,000 share options at a strike price of NOK 67.35 each, the company said on October 28, 2026. The grant was made under Oncoinvent's long-term incentive program, news.cision.com reported.

How the Oncoinvent Option Grant Is Structured

Each option gives the right to acquire one share in Oncoinvent when exercised. The options were granted without consideration, and the strike price equals the volume weighted average share price on the last day before the grant.

No options vest during the first 12 months after the grant letter. Then 13/48 of the options vest in the 13th month, and the rest vest in equal monthly instalments of 1/48, provided the holder remains employed. Options not exercised lapse seven years after the grant date.

Following the grant, Trnkova holds 20,000 options in the company. The board said it sees an option program as an important element in attracting and retaining employees, and considers the program terms and this allocation to be at the market for comparable peers.

Oncoinvent said the information is subject to disclosure requirements under Regulation (EU) 596/2014 (MAR) Article 19 and Section 5-12 of the Norwegian Securities Trading Act. Chief Executive Officer Oystein Soug is listed as the contact for further information.

Oncoinvent's Earlier Leadership and Funding Moves

According to akta.pro company records, Oncoinvent appointed Dr. Ramzi Amri as Chief Financial Officer effective mid-January 2026, joining from Galapagos NV with prior McKinsey & Company experience to support the post-merger public-company finance function.

The same records show Oncoinvent closed a fully underwritten rights issue of 260,000,000 new shares raising NOK 130 million (approximately USD 12 million) in December 2025, ahead of the planned Phase 2 interim readout. In October 2025 it completed a strategic merger with BerGenBio ASA and uplisted to the Oslo Stock Exchange as Oncoinvent ASA under the ticker ONCIN, issuing 117,554,012 shares to former Oncoinvent shareholders.

Radspherin Role and Phase 3 Preparation

Oncoinvent appointed Dr Zuzana Jiráková Trnková as Chief Medical Officer effective November 4, 2026, to lead Phase 3 preparations for Radspherin, news.cision.com reported on October 28, 2026.

Oncoinvent is developing Radspherin, a receptor-independent alpha radiation therapy designed to destroy residual micrometastases in the abdominal cavity. Its initial clinical focus is ovarian and colorectal cancer patients after surgical removal of the primary tumor and visible metastases in the peritoneum.

Radspherin Trial Timelines

Oncoinvent said interim data from an ongoing, randomized, controlled phase 2 ovarian cancer trial is expected in the second half of 2026 for safety and the first half of 2027 for early efficacy.